An Anti-angiogenic Reverse Thermal Gel as a Drug-Delivery System for Age-Related Wet Macular Degeneration

Reverse thermal gels have numerous biomedical implications, as they undergo physical gelation upon temperature increases and can incorporate biomolecules to promote tissue repair. Such a material is developed for the sustained release of bevacizumab (Avastin), a drug used to treat age‐related macula...

Full description

Saved in:
Bibliographic Details
Published in:Macromolecular bioscience 2013-04, Vol.13 (4), p.464-469
Main Authors: Park, Daewon, Shah, Veeral, Rauck, Britta M., Friberg, Thomas R., Wang, Yadong
Format: Article
Language:English
Subjects:
age-related wet macular degeneration
Angiogenesis Inhibitors - therapeutic use
Animals
Antibodies, Monoclonal, Humanized
Bevacizumab
Biodegradability
Biological effects
Biomedical materials
Cattle
compatibility
Degeneration
Delayed-Action Preparations - therapeutic use
Drug Delivery Systems - methods
Drugs
Endothelium, Corneal - cytology
Humans
hydrogels
Hydrogels - therapeutic use
Immunoassay
In vitro testing
retinal cells
Sustained release
Sustaining
Temperature
Urethanes
Wet Macular Degeneration - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Reverse thermal gels have numerous biomedical implications, as they undergo physical gelation upon temperature increases and can incorporate biomolecules to promote tissue repair. Such a material is developed for the sustained release of bevacizumab (Avastin), a drug used to treat age‐related macular degeneration. The polymer, poly(ethylene glycol)‐poly(serinol hexamethylene urethane) (ESHU), forms a physical gel when heated to 37 °C and shows good cytocompatibility with ocular cells. ESHU is capable of sustaining bevacizumab release over 17 weeks in vitro, and the release kinetics can be altered by changing the drug dose and the ESHU concentration. These results suggest that ESHU is biologically safe, and suitable for ocular drug delivery. An injectable and biodegradable reverse thermal gel, ESHU, is capable of sustaining the release of bevacizumab over 17 weeks in vitro. ESHU is not toxic to ocular cell types, demonstrating its potential as an intravitreal drug‐delivery system.
ISSN:1616-5187
1616-5195
DOI:10.1002/mabi.201200384